Accuray Incorporated (ARAY) SEC Filings & Earnings Calls
EquiReason read 25 Accuray Incorporated SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-16 — Proxy statement for 2026 annual meeting; discloses TCW governance rights via $55M preferred stock issuance, new CEO compensation, and 0% bonus funding due to missed targets..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 15.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
16 Oct 2026DEF 14AProxy statement for 2026 annual meeting; discloses TCW governance rights via $55M preferred stock issuance, new CEO compensation, and 0% bonus funding due to missed targets.open
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $402M | |
| Orders (net of cancellations) · FY2026 | $192M | |
| Adjusted EBITDA Margin · FY2026 | 2.6% | |
| Net Income (Loss) · FY2026 | $-49M | +2992% y/y |
| Total Shareholder Return (3-year cumulative) · FY2026 | $7.00 | -80% y/y |
Risks flagged
Debt covenant and liquidity risk
“The Third Amendment amends the Financing Agreement to, among other things, (i) provide a covenant holiday through December 31, 2027 with respect to the Company's compliance with the Total Leverage Ratio and Fixed Charge Coverage Ratio” · word for word
Performance miss and bonus elimination
“Based on our actual corporate performance results, our Board and our Compensation Committee approved 0% funding of the cash incentive awards for fiscal 2026” · word for word
Stock price decline and dilution
“closing market price per share on the Nasdaq Global Select Market of our common stock on June 30, 2026 ... $0.26”
13 Oct 20268-K · 5.02Director Mika Nishimura will not stand for re-election at the 2026 annual meeting; no disagreement with company. Routine board refreshment.open
Risks flagged
No material risk from this director departure; no disagreement disclosed.
“Ms. Nishimura's decision not to stand for re-election is not due to any disagreement with the Company or the Board.” · word for word
6 Oct 20268-K · 5.02, 5.07, 8.01Stockholders approved key financing proposals including share issuance, authorized share increase to 400M, and reverse stock split (1:15-1:40) to regain Nasdaq compliance. New director appointed.open
Risks flagged
Reverse stock split indicates bid price non-compliance with Nasdaq; potential dilution from authorized share increase.
“Reverse stock split... to allow the Company to regain compliance with Nasdaq listing requirements for the bid price.” · word for word
2 Sep 2026SC 13D/AAccuray entered into a $55M preferred stock issuance and debt restructuring with covenant holiday, indicating severe financial distress and potential dilution.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-09-02 | 18.7% | |
| Preferred stock issuance amount · 2026-07-29 | $55M | |
| Debt converted to equity · 2026-07-29 | $40M |
Risks flagged
Debt default risk
“The Third Amendment amends the Financing Agreement to, among other things, (i) provide a covenant holiday through December 31, 2027 with respect to the Issuer's compliance with the Total Leverage Ratio and Fixed Charge Coverage Ratio financial covenants” · word for word
Severe dilution risk
“the Issuer issued to TCW Rescue Financing a Common Stock Purchase Warrant to purchase 7,987,743 shares of Common Stock and to TCW Direct Lending a Common Stock Purchase Warrant to purchase 598,114 shares of Common Stock (collectively, the "July Penny Warrants"). The July Penny Warrants have an exercise price of $0.01 per share” · word for word
2 Sep 2026SC 13D/AAccuray entered into a $55M preferred stock issuance and debt restructuring with covenant holiday, indicating severe financial distress and potential dilution.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-09-02 | 18.7% | |
| Preferred stock issuance amount · 2026-07-29 | $55M | |
| Debt converted to equity · 2026-07-29 | $40M |
Risks flagged
Debt default risk
“The Third Amendment amends the Financing Agreement to, among other things, (i) provide a covenant holiday through December 31, 2027 with respect to the Issuer's compliance with the Total Leverage Ratio and Fixed Charge Coverage Ratio financial covenants” · word for word
Severe dilution risk
“the Issuer issued to TCW Rescue Financing a Common Stock Purchase Warrant to purchase 7,987,743 shares of Common Stock and to TCW Direct Lending a Common Stock Purchase Warrant to purchase 598,114 shares of Common Stock (collectively, the "July Penny Warrants"). The July Penny Warrants have an exercise price of $0.01 per share” · word for word
27 Aug 202610-KAnnual report (10-K) for FY2026 discloses material negative impact from tariffs on China revenue and gross margins, ongoing liquidity and covenant risks, and a product recall.earningsopen
Figures in the filing · each found in the filing text
| JV revenue as % of total net revenue · FY2026 | 16.0% | |
| Tariff refund claim balance · 2026-06-30 | $9M |
Risks flagged
Tariff cost pressure and China revenue decline
“To date, tariff impacts have materially reduced our China product revenues and adversely affect our gross margins.” · word for word
Debt covenant compliance and liquidity risk
“If we are unable to obtain necessary waivers or relevant amendments as required and the debt under such credit facility is accelerated, we would be required to obtain replacement financing at prevailing market rates, which may not be available to us on favorable terms or at all.” · word for word
Single-source supplier dependency
“We currently depend on single source suppliers for some of the critical components necessary to assemble the CyberKnife and TomoTherapy platforms” · word for word
Product recall and quality risk
“we initiated a voluntary recall on CyberKnife in May 2026 related to collimator retention during exchange.” · word for word
Customer concentration risk
“The JV represented approximately 16% and 26% of our total net revenue during the years ended June 30, 2026 and 2025, respectively.” · word for word
24 Aug 2026DEF 14ACompany proposes a $55M financing transaction involving $15M cash investment, $40M debt-to-equity conversion, issuance of warrants, and a reverse stock split, with massive potential dilution and TCW gaining significant control.open
Figures in the filing · each found in the filing text
| Series A Preferred Stock issued · 2026-07-29 | 55,000 | |
| Cash investment from preferred stock · 2026-07-29 | $15M | |
| Debt converted to equity · 2026-07-29 | $40M | |
| Warrants issued · 2026-07-29 | 15,253,473 | |
| Common stock outstanding · 2026-08-21 | 119,439,307 | |
| Authorized common stock (proposed increase) · proposed | 400,000,000 | |
| Cancelled warrants · 2026-07-29 | 27,600,000 |
Risks flagged
Massive dilution risk
“resulting in the issuance of 110,000,000 shares of Common Stock, which would increase our Common Stock outstanding as of August 21, 2026 from 119,439,307 shares to 229,439,307 shares (an increase of 92%).” · word for word
Nasdaq delisting risk
“we cannot assure you that Nasdaq will not exercise its discretionary authority to make a delisting determination with respect to our Common Stock” · word for word
TCW control risk
“TCW and its affiliates will have significant influence over us following the conversion of the Series A Preferred Stock and the exercise of the Warrants, if any, and their interests may conflict with those of our other stockholders in the future.” · word for word
Non-approval termination risk
“If the Purchase Agreement is terminated for failure to obtain stockholder approval, (i) the Cash Investment will automatically be deemed to be an Obligation...and (ii) we will be required to pay a fee in an amount equal to $15.0 million” · word for word
19 Aug 20268-K · 2.02, 7.01Accuray reported Q4 FY2026 revenue of $100.9M (down 21% YoY), product revenue down 42%, net loss of $1.9M, and gross product orders of $37.7M (down 55% YoY). Full-year revenue down 12%, net loss widened to $49.2M. Transformation plan deliveearningsopen
Figures in the filing · each found in the filing text
| Total net revenue · Q4-2026 | $101M | -21% y/y |
| Product revenue · Q4-2026 | $41M | -42% y/y |
| Service revenue · Q4-2026 | $60M | +6% y/y |
| Gross profit · Q4-2026 | $35M | -10% y/y |
| Gross margin · Q4-2026 | 34.8% | |
| Net loss · Q4-2026 | $-2M | -273% y/y |
| Adjusted EBITDA · Q4-2026 | $13M | +37% y/y |
| Gross product orders · Q4-2026 | $38M | -55% y/y |
| Book to bill ratio · Q4-2026 | $0.90 | -25% y/y |
| Order backlog · FY2026 | $313M | -27% y/y |
Risks flagged
Significant decline in product orders and backlog indicates weakening demand for capital equipment, potentially due to geopolitical uncertainty and tariff pressures.
“Gross product orders down 55% YoY in Q4; backlog down 27% YoY. CEO cited 'ongoing geopolitical uncertainty, tariff pressures, and market volatility'.”
No FY2027 guidance provided, signaling high uncertainty about near-term outlook.
“The filing states 'guidance for fiscal 2027 at this time' is not provided.”
Widening net loss and negative free cash flow (implied) raise concerns about financial sustainability despite liquidity improvement.
“FY2026 net loss of $49.2M vs $1.6M prior year; cash only $41.2M.”
6 Aug 20268-K · 3.01Accuray received approval to transfer listing from Nasdaq Global Select to Capital Market due to non-compliance with bid price requirement; granted 180-day extension to Feb 1, 2027.open
Risks flagged
Failure to regain compliance by Feb 1, 2027 could lead to delisting, severely impacting liquidity and investor confidence.
“granted an additional 180 day period, or until February 1, 2027, to demonstrate compliance with the $1.00 bid price requirement of The NASDAQ Capital Market.” · word for word
29 Jul 20268-K · 1.01, 3.02, 5.02, 8.01Accuray entered into Securities Purchase Agreement with investors; two board members resigned; warrant issued; amendment to financing agreement; press release issued.open
Risks flagged
Dilution from equity offering and warrant; board departures may indicate governance changes
“Securities Purchase Agreement; warrant issuance; two board members resigned.”
22 May 2026SC 13D/ATCW Group received warrants as condition for delayed draw term loan to Accuray, increasing potential dilution.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-05-19 | 13.7% |
Risks flagged
Share dilution from warrant exercise
“The May Warrants were issued to the holders thereof in connection with the making of a Delayed Draw Term Loan.” · word for word
22 May 2026SC 13D/ATCW Group received warrants as condition for delayed draw term loan to Accuray, increasing potential dilution.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-05-19 | 13.7% |
Risks flagged
Share dilution from warrant exercise
“The May Warrants were issued to the holders thereof in connection with the making of a Delayed Draw Term Loan.” · word for word
6 May 20268-K · 2.02, 7.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsopen
Guidance
Company withdrew full-year guidance, a strong negative signal.
Risks flagged
Guidance withdrawal indicates potential operational or market challenges.
“withdrawal of its financial guidance for fiscal year 2026”
6 May 202610-QAccuray reported a significant revenue decline, net loss, and gross margin contraction, with restructuring and going concern risks.open
Figures in the filing · each found in the filing text
| Total Net Revenue · Q3-2026 | $105M | -7% y/y |
| Product Revenue · Q3-2026 | $50M | -13% y/y |
| Service Revenue · Q3-2026 | $55M | -1% y/y |
| Net Loss · Q3-2026 | $-12M | |
| Gross Margin % · Q3-2026 | 24.1% | |
| Cash and Equivalents · 2026-03-31 | $38M | |
| Backlog · 2026-03-31 | $356M | |
| Gross Orders · Q3-2026 | $49M | -32% y/y |
| Net Orders · Q3-2026 | $23M | -52% y/y |
| Restructuring Charges · Q3-2026 | $7M |
Guidance
Expects gross margins and net income to be adversely affected through at least FY2026; expects US revenue impact through FY2026
Management expects continued adverse impact from tariffs, supply chain, and US market weakness through FY2026.
Risks flagged
Debt Covenant Compliance Risk
“The Company, however, is unable to predict with certainty the impact that geopolitical and macroeconomic conditions... will have on its ability to maintain compliance with the covenants contained in the Amended Financing Agreement” · word for word
Nasdaq Delisting Risk
“On February 2, 2026, the Company received a notice from the Nasdaq Listing Qualifications Department... indicating that... the Company was no longer in compliance with Nasdaq Listing Rules 5550(a)(2) (the 'Bid Price Rule')” · word for word
Tariff Exposure Risk
“If existing tariffs associated with U.S.-China trade increase, we would expect minimal shipments to China despite customer demand.” · word for word
Going Concern Risk
“The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by geopolitical and macroeconomic conditions.” · word for word
17 Apr 2026SC 13D/AThe TCW Group, Inc. filed an amended Schedule 13D disclosing an 11.5% beneficial ownership stake in Accuray Inc. via warrants issued in connection with financing amendments.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-04-17 | 11.5% | |
| Warrant shares · 2026-04-17 | 15,467,952 |
17 Apr 2026SC 13D/AThe TCW Group, Inc. filed an amended Schedule 13D disclosing an 11.5% beneficial ownership stake in Accuray Inc. via warrants issued in connection with financing amendments.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-04-17 | 11.5% | |
| Warrant shares · 2026-04-17 | 15,467,952 |
17 Feb 202610-K/A10-K/A provides detailed risk factors and operational challenges; signals are supported by specific evidence of tariff impacts, cost pressures, and internal control weaknesses.open
Risks flagged
Tariff and trade war exposure
“Enhanced international tariffs, including tariffs imposed by the United States and China that affect our products or components within our products, other trade barriers or a global trade war could decrease the volume of product sales in China and increase our costs.”
High debt and covenant compliance risk
“We have substantial indebtedness... In the past, we have not been in compliance with certain financial covenants relating to our indebtedness and have been required to obtain waivers to avoid defaulting under such indebtedness.”
Supply chain and single-source supplier dependency
“We currently depend on single source suppliers for some of the critical components necessary to assemble the CyberKnife and TomoTherapy platforms.”
Material weaknesses in internal controls
“We have identified material weaknesses in our system of internal controls as of June 30, 2025 and are in the process of remediation.”
17 Feb 202610-QQuarterly results show declining JV revenue concentration and ongoing debt covenant risks; no explicit beat or miss stated.earningsopen
Figures in the filing · each found in the filing text
| JV revenue concentration · Joint Venture · Q2-2026 | 17.0% |
Risks flagged
Debt covenant non-compliance and going concern risk
“In the past, we have not been in compliance with certain financial covenants relating to our indebtedness and have been required to obtain waivers to avoid defaulting under such indebtedness.” · word for word
Tariff impact on margins and China sales
“These tariffs affect component parts including the linear accelerator for our CyberKnife platforms, which we manufacture in China and import into the U.S., as well as other components that we import into the U.S. from other suppliers, which could significantly impact the cost of these parts.” · word for word
Single-source supplier dependency
“We currently depend on single source suppliers for some of the critical components necessary to assemble the CyberKnife and TomoTherapy platforms” · word for word
Customer concentration risk
“The JV represented approximately 17% and 30% of our total net revenue during the three months ended December 31, 2025 and 2024, respectively” · word for word
17 Feb 202610-Q/AQuarterly results show declining JV revenue concentration and ongoing debt covenant risks; no explicit beat or miss stated.earningsopen
Figures in the filing · each found in the filing text
| JV revenue concentration · Joint Venture · Q1-2026 | 15.0% |
Risks flagged
Debt covenant non-compliance and going concern risk
“In the past, we have not been in compliance with certain financial covenants relating to our indebtedness and have been required to obtain waivers to avoid defaulting under such indebtedness.” · word for word
Tariff impact on margins and China sales
“These tariffs affect component parts including the linear accelerator for our CyberKnife platforms, which we manufacture in China and import into the U.S., as well as other components that we import into the U.S. from other suppliers, which could significantly impact the cost of these parts.” · word for word
Single-source supplier dependency
“We currently depend on single source suppliers for some of the critical components necessary to assemble the CyberKnife and TomoTherapy platforms” · word for word
Customer concentration risk
“Our JV represented approximately 15% and 32% of our total net revenue for the three months ended September 30, 2025 and 2024, respectively” · word for word
5 Nov 202510-QAccuray reported Q1 FY2026 revenue of $93.9M (-7% YoY), gross margin of 28.3% (-560bps), and net loss of $21.7M (vs -$4.0M), with China revenue collapsing 55% and restructuring initiated.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $94M | -8% y/y |
| Product revenue · Q1-2026 | $37M | -23% y/y |
| Service revenue · Q1-2026 | $57M | +7% y/y |
| Gross profit margin · Q1-2026 | 28.3% | |
| Net loss · Q1-2026 | $-22M | +448% y/y |
| Gross orders · Q1-2026 | $40M | -29% y/y |
| Order backlog · Q1-2026 | $396M | -16% y/y |
| Cash and cash equivalents · Q1-2026 | $63M | |
| Total debt, net · Q1-2026 | $140M | |
| Interest expense · Q1-2026 | $8M | +173% y/y |
Guidance
Gross margin and cash flow pressure through FY2026; China sales adversely impacted through H1 FY2026; U.S. demand weakness through FY2026
Management expects continued gross margin and cash flow pressure through FY2026 from inflation, supply chain, and tariffs. China sales expected to be adversely impacted through at least H1 FY2026. U.S. demand weakness to persist through FY2026. Transformation plan announced with new CEO.
Risks flagged
Covenant compliance risk under Financing Agreement
“The Company, however, is unable to predict with certainty the impact that geopolitical and macroeconomic conditions... will have on its ability to maintain compliance with the covenants contained in the Financing Agreement” · word for word
High effective interest rate on debt
“Term Loan Facility due 2030 23.8%”
China tariff and revenue concentration risk
“If existing tariffs increase, we would expect minimal shipments to China despite customer demand.” · word for word
U.S. demand weakness for radiotherapy equipment
“reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted net revenue since fiscal year 2024, and we expect this will continue to have an impact through fiscal year 2026.” · word for word
Supply chain and inflation headwinds through FY2026
“we currently expects that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistics expenses through at least fiscal year 2026” · word for word
5 Nov 20258-K · 2.02, 7.01Accuray reports soft Q1 FY2026: revenue $93.9M (-7% YoY), product revenue $37.2M (-23%), net loss $21.7M vs $4.0M loss, Adj EBITDA loss $4.1M vs +$3.1M. Gross orders $39.6M vs $55.4M. Backlog $395.7M (-16%). Reaffirms FY guidance: revenue $earningsopen
Figures in the filing · each found in the filing text
| Total net revenue · Q1-2026 | $94M | -7% y/y |
| Product revenue · Product · Q1-2026 | $37M | -23% y/y |
| Service revenue · Service · Q1-2026 | $57M | +7% y/y |
| Gross profit · Q1-2026 | $27M | -23% y/y |
| Net loss · Q1-2026 | $-22M | +443% y/y |
| Adjusted EBITDA · Q1-2026 | $-4M | -232% y/y |
| Gross product orders · Q1-2026 | $40M | -29% y/y |
| Order backlog · Q1-2026 | $396M | -16% y/y |
| Cash, cash equivalents, and short-term restricted cash · Q1-2026 | $64M |
Guidance
FY2026 revenue $471M-$485M; Adjusted EBITDA $31M-$35M
Reaffirmed FY2026 guidance despite soft Q1, indicating management expects improvement in remaining quarters.
Risks flagged
Sharp decline in product orders and backlog signals weakening demand for radiotherapy capital equipment.
“Gross product orders was $39.6 million ... compared to $55.4 million. Order backlog ... 16 percent lower.”
Net loss widened significantly to $21.7M from $4.0M, driven by revenue decline and restructuring charges.
“Net loss was $21.7 million ... as compared to a net loss of $4.0 million.” · word for word
Restructuring plan and CEO change indicate organizational instability; execution risk remains.
“initiated a restructuring plan aimed at reducing costs ... Appointed Steve La Neve as President and Chief Executive Officer.”
Accuray Incorporated — questions
- What did Accuray Incorporated file recently?
- 25 SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-16 — Proxy statement for 2026 annual meeting; discloses TCW governance rights via $55M preferred stock issuance, new CEO compensation, and 0% bonus funding due to missed targets.
Every figure on this page comes from Accuray Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.